

www.erectistim.com

info@erectistim.com

THE PROBLEM


- Over 2.15 Billion men worldwide suffer from some level of erectile dysfunction with *no available cure*
- ED affects up to
 50% of men age 40 -70
- Nearly \$5B spent annually on ED drugs that have adverse side effects, high costs and provide only temporary relief

THE CURRENT SOLUTIONS

	OPTIONS Oral Medication, Injection, Cream, Suppository, Testosterone Replacement	 STRENGTHS Easy to get RX Non-Invasive Lasts Hours Temporary Fix for ED 	 WEAKNESSES Pain Numbness Difficulty Sleeping Sensitivity to Light Priapism
Priapus Shot®	Use Platelet Rich Plasma (PRP) with Umbilical Cord Stem Cells	 Safer, Less Invasive and Less Expensive Than Surgical Procedures Greater Stamina and Firmer Erections Improved Blood Flow to Penis 	 Bruising Allergic Reaction on Site Pain from Injection Site Sensitivity
GAINSWave	Low-Intensity Extra-Corporeal Shockwave Therapy (LI-ESWT)	 Less Invasive and Less Expensive Than Surgical Procedures Improved Blood Flow to Penis 	 Can Last Less Than a Few Months Expensive Treatments Can Be Painful Not Clinically Available in Most Locations

THE **<u>RIGHT</u>** SOLUTION:






THE **<u>RIGHT</u>** SOLUTION



MyoSTIM ED is the only therapy to address all three major underlying causes of ED:

- 1. Lack of Blood Flow
- 2. Deteriorated Muscle
- 3. Damaged Nerves



THE **<u>RIGHT</u>** SOLUTION:



BIOELECTRIC SIGNALING THERAPY




INDICATIONS

- Safer, Non-Invasive, Less Expensive Than Surgical Procedures
- Greater Stamina and Firmer Erections
- Improved Blood Circulation of the Penis
- In-Clinic and At-Home Treatments
 - Sustained Treatment Effects
- **The Goal of MyoSTIM ED:** To treat all the underlying causes of ED in as little as 4 weeks of treatment. Sustained benefit and durability without further treatment proven for at least 3 months.
- MyoSTIM ED uses an FDA 510K market-cleared bioelectric stimulator to deliver 6 pre-programmed signals via easy-toapply surface electrodes. The precise signals stimulate improved blood supply and stem cell homing to induce both muscle and nerve regeneration for improved sexual performance.

THE SCIENCE



Precise Bioelectric Signaling of Pro-Regenerative Proteins



Patent-pending precision bioelectric signals control release of natural proteins that enable erectile dysfunction recovery.

THE SCIENCE: ErectiStim Plus



20+ patented or patent-pending bioelectric signaling sequences for organ and tissue regeneration and recovery Includes pending patents on:

- Stem cell homing signal
- Bioelectric inflammation management signaling sequences
- Follistatin muscle regeneration signaling
- Nerve regeneration signaling
- Neuro modulation signaling
- 15+ component organ regeneration composition
- Combination bioelectric stimulator + micro infusion pump + organ regeneration composition

PROPRIETARY TECHNOLOGY

THE DATA: PROVEN EFFECTIVE 5 Clinical Trials >100 Patients

- Comparing VEGF Alone vs MyoStim
 6-Signal Regimen for 4 and 8 Weeks
- Examining Durability of Benefit for 3 Months Post Treatment
- Examining Benefit to Post Prostatectomy Patients



MyoStim Trials

ED I: VEGF alone (4 wks)

ED II: VEGF vs MyoStim (4 wks)

ED III: MyoStim follow-up (3 mos)

ED IV: Myostim (8 wks)

ED V: MyoStim Prostatectomy (8 wks)


THE **DATA:**




Subject Characteristics: Means of All Five Studies n= 81 (another 25 in follow up)

ŀ			I	III	IV	V
	Number	11	9	19	20	10
	Age (yr)	59 ± 5	53 ± 3	53 ± 2	57 ± 2	61 ± 3
	Race Caucasian African	19 (86%) 3 (14%)				
	Previous Use of PDEI	> 4 Weeks Washout				
	Smokers n(%)	12 (15%)	1 (11%)	2 (11%)		
	Testosterone Supplement	0 (0%)				
	Baseline ED Score					
	EHS	1.7 ± 0.1	1.2 ± 0.1	1.4 ± 0.1	1.3 ± 0.1	1.6 ± 0.2
	IIEF-5	11 ± 1	10 ± 1	11 ± 1	10 ± 1	10 ±1


MyoStim ED II Study International Index of Erectile Function Questionnaire




MyoStim ED International Index of Erectile Function Questionnaire




MyoStim ED Erection Hardness Score



MyoStim ED II Study



MyoStim ED II Study Total Testosterone Level




THE **OPPORTUNITY**



GLOBAL ED DRUG MARKET

The global ED market continues to expand despite revenue declines from:

- Patent expiration of key drugs
- Side effects from existing drugs negatively affecting growth
- Proliferation of cost-effective counterfeit drugs



GLOBAL ED DRUG MARKET GROWTH: 2018-2022

Sources: The Business Research Company, Sept. 2019; Grand View Research, July 2016

THE **TEAM**





Howard Leonhardt Executive Chairman & CEO, Co-Founder



Prof. Cristiane Carboni Chief Scientific Officer



Dr. Leslie Miller Chief Medical Officer



Alex Richardson VP Engineering & Product Development



Dr. Brett Burton Director of R&D & Startup Launch



Dr. Jorge Genovese VP Bioelectric Regeneration Research



Jeremy Koff VP Strategic Development



Brian Hardy Director of Marketing

THE **PLAN**



Five Phase II-III Clinical Trials Over 100 Patients

> Added Bioelectric Signals for Improved Nerve Regeneration

> > Q3

Added Bioelectric Signals for Improved Inflammation Management

Q4

Exit to Strategic Partner

Q2

Q3

2020

Q4

Q1



2019

Q2

THE NEXT STEP



OPPORTUNITY TO LEAD ED MARKET WITH BEST-IN-CLASS TECHNOLOGY

Premium Pricing Due to Better Results and Fewer Side Effects = HIGHER GROSS PROFIT

20 YEARS PATENT LIFE FOR:

- Stem Cell Homing
- New Non-Leaky Blood Vessel Formation
- Muscle and Nerve Regeneration
- Inflammation Management

EXPAND THE MARKET:

- For Those Averse to Oral Treatments
- In-Clinic and At-Home Therapies
- Patents for Ultra Premium Product: ErectiStim Plus - Highest Gross Margins for Treating Most Severe Cases

 Angle Cases
 Angle Cases

